

Pharmaleads to present at BioTrinity 2018 in London

Paris, France, [19 April 2018] - Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, will present at BioTrinity 2018 in London on Tuesday, April 24th at 3.35pm.

Michel Wurm, VP Medical Affairs, will introduce Pharmaleads and its innovative compounds, PL265 and PL37, which protect enkephalins, the key elements of the body's physiological pain modulation system, from degradation, thereby durably increasing their concentrations in the nervous system. The size of the chronic severe pain market is estimated at more than 200 million people in Europe and in the United States.

BioTrinity is Europe's leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 12th year, draws attendees from approximately 30 countries and includes close to 120 life sciences investors, as well as industry leaders from global pharma.

-Ends-

For more information, please contact:

Pharmaleads

Michel Wurm, MD, VP, Medical Affairs, Strategy and Business Development

michel.wurm@pharmaleads.com

+33 (0) 1 44 06 70 04

+33 (0) 6 09 97 81 04

Media Relations

Citigate Dewe Rogerson

Sylvie Berrebi, Marine Perrier, David Dible

pharmaleads@citigatedewerogerson.co.uk

Tel: +44 (0)20 7638 9571

About Pharmaleads

Pharmaleads is an emerging pharmaceutical company developing innovative products for the management of acute and chronic severe pain, a growing market with significant unmet medical need. Pharmaleads' drugs are based on its deep knowledge and understanding of enkephalins, a key element of the body's natural pain management system.

Pharmaleads' compounds, (Dual ENKephalinase inhibitors) DENKIs, aim to protect enkephalins, hence increasing their local concentrations and thereby inducing a physiological analgesia which improves pain management.

Pharmaleads has two compounds in clinical development which are targeting multi-billion markets: PL265 is being developed for the treatment of neuropathic pain (oral) and ocular pain/dry eye syndrome (eye drops). PL37 is being developed for the treatment of post-surgical / traumatic / breakthrough cancer pain as a non-addictive substitute for injectable opiates (IV).

Pharmaleads is headquartered in Paris, France, and is funded by private investors.

For more information about Pharmaleads please visit www.pharmaleads.com